Drug:
Reaction: ACCIDENTAL EXPOSURE TO PRODUCT
20250101 - 20251231
No. 301 - 400
| No. | safetyreportid |
occurcountry |
patientonsetage |
patientsex 1:M 2:F |
|---|---|---|---|---|
Adverse reaction |
||||
Drug (openfda.generic_name, medicinalproduct) |
||||
| 301 | 25092155 |
US |
||
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 302 | 25092266 |
US |
58 | 2 |
Injection site bruising, Accidental exposure to product, Product preparation error, Incorrect dose administered by device, Injection site pain, |
||||
EVOLOCUMAB, |
||||
| 303 | 25092466 |
US |
2 | |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 304 | 25092471 |
US |
2 | |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 305 | 25092496 |
US |
52 | 1 |
Off label use, Accidental exposure to product, Exposure via skin contact, |
||||
INSULIN GLARGINE, |
||||
| 306 | 25092645 |
US |
56 | 2 |
Off label use, Accidental exposure to product, Exposure via skin contact, |
||||
INSULIN GLARGINE, |
||||
| 307 | 25092812 |
US |
62 | 2 |
Accidental exposure to product, Exposure via skin contact, |
||||
INSULIN GLARGINE, |
||||
| 308 | 25092878 |
US |
||
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 309 | 25092914 |
US |
2 | |
Injury associated with device, Accidental exposure to product, Occupational exposure to product, |
||||
PEGFILGRASTIM, |
||||
| 310 | 25093106 |
US |
14 | 2 |
Accidental exposure to product, Mydriasis, |
||||
EPINEPHRINE, ADRENALINUM, EPINEPHRINE, ADRENALINUM, EPINEPHRINE, ADRENALINUM, EPINEPHRINE, ADRENALINUM, ALBUTEROL SULFATE, ALBUTEROL, ALBUTEROL SULFATE, ALBUTEROL, ALBUTEROL SULFATE, ALBUTEROL, ALBUTEROL SULFATE, ALBUTEROL, OXYGEN, 0XYGEN, OXYGEN, 0XYGEN, OXYGEN, 0XYGEN, OXYGEN, 0XYGEN, ROCURONIUM, ROCURONIUM BROMIDE, METHYLPREDNISOLONE, MAGNESIUM SULFATE, MAGNESIUM SULFATE HEPTAHYDRATE, MAGNESIUM SULFATE IN WATER FOR, AMINOPHYLLINE, FENTANYL, |
||||
| 311 | 25093117 |
US |
||
Accidental exposure to product, No adverse event, |
||||
IOHEXOL, |
||||
| 312 | 25093196 |
US |
2 | |
Injection site haemorrhage, Injection site bruising, Diarrhoea, Product knowledge deficit, Wrong technique in product usage process, Incorrect dose administered by device, Accidental exposure to product, |
||||
SOMATROPIN, SOMATROPIN, SOMATROPIN, SOMATROPIN, |
||||
| 313 | 25093358 |
US |
2 | |
Device malfunction, Accidental exposure to product, Product dose omission issue, |
||||
SECUKINUMAB, |
||||
| 314 | 25093497 |
US |
66 | 2 |
Injection site haemorrhage, Accidental exposure to product, |
||||
FREMANEZUMAB-VFRM, |
||||
| 315 | 25093550 |
US |
2 | |
Device issue, Incorrect dose administered by device, Accidental exposure to product, |
||||
OFATUMUMAB, |
||||
| 316 | 25093732 |
US |
75 | 2 |
Accidental exposure to product, Device difficult to use, Injection site haemorrhage, Drug dose omission by device, |
||||
EVOLOCUMAB, |
||||
| 317 | 25093742 |
US |
2 | |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 318 | 25093750 |
US |
78 | 2 |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 319 | 25093841 |
US |
68 | 1 |
Malaise, Accidental exposure to product, Device difficult to use, Drug dose omission by device, |
||||
EVOLOCUMAB, EVOLOCUMAB, |
||||
| 320 | 25093992 |
US |
2 | |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 321 | 25094011 |
US |
60 | 2 |
Rash macular, Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 322 | 25094686 |
US |
81 | 2 |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 323 | 25094836 |
US |
11 | 2 |
Accidental exposure to product, Exposure via skin contact, Inappropriate schedule of product administration, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 324 | 25095068 |
US |
1 | |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 325 | 25095188 |
US |
||
Eye irritation, Vision blurred, Accidental exposure to product, |
||||
| 326 | 25095227 |
US |
||
Rash erythematous, Chapped lips, Lip swelling, Accidental exposure to product, |
||||
| 327 | 25095386 |
US |
54 | 2 |
Drug dose omission by device, Accidental exposure to product, Device leakage, |
||||
PEGFILGRASTIM, PEGFILGRASTIM, |
||||
| 328 | 25095403 |
US |
43 | 1 |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 329 | 25095690 |
US |
2 | |
Exposure via skin contact, Accidental exposure to product, |
||||
ALBUTEROL SULFATE, |
||||
| 330 | 25095801 |
US |
61 | 1 |
Device issue, Syringe issue, Accidental exposure to product, Product dose omission issue, |
||||
USTEKINUMAB, USTEKINUMAB, |
||||
| 331 | 25096041 |
US |
90 | 1 |
Accidental exposure to product, Headache, Injection site haemorrhage, Device difficult to use, Drug dose omission by device, |
||||
EVOLOCUMAB, ACETAMINOPHEN, GUAIFENESIN, AND PHENYLEPHRINE HYDROCHLORIDE, ACETAMINOPHEN, |
||||
| 332 | 25096320 |
DE |
2 | |
Device deployment issue, Accidental exposure to product, Product dose omission issue, Injection site haemorrhage, |
||||
GUSELKUMAB, |
||||
| 333 | 25096697 |
US |
35 | 2 |
Fear of injection, Accidental exposure to product, Incorrect dose administered, Exposure via skin contact, |
||||
ADALIMUMAB-ADAZ, |
||||
| 334 | 25096935 |
US |
11 | 2 |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 335 | 25097037 |
US |
41 | 2 |
Injection site pain, Accidental exposure to product, Incorrect dose administered by device, Condition aggravated, |
||||
ERENUMAB-AOOE, |
||||
| 336 | 25097077 |
US |
37 | 2 |
Accidental exposure to product, Device leakage, Incorrect dose administered, |
||||
SECUKINUMAB, ALBUTEROL SULFATE, ALBUTEROL, |
||||
| 337 | 25097082 |
US |
63 | 2 |
Syringe issue, Underdose, Accidental exposure to product, |
||||
USTEKINUMAB, USTEKINUMAB, |
||||
| 338 | 25097180 |
US |
||
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 339 | 25086730 |
US |
77 | 2 |
Accidental exposure to product, Drug dose omission by device, Injection site pain, |
||||
EVOLOCUMAB, |
||||
| 340 | 25087037 |
US |
21 | 2 |
Eye swelling, Accidental exposure to product, Exposure via eye contact, |
||||
TREPROSTINIL, TREPROSTINIL, SODIUM CHLORIDE, SODIUM CHLORIDE INJECTION, SODIUM CHLORIDE TABLET, NORMAL SALT TABLETS, MACITENTAN, KETAMINE HYDROCHLORIDE, TADALAFIL, SELEXIPAG, CLONIDINE, KETOPROFEN, LIDOCAINE HYDROCHLORIDE, LIDOCAINE HYDROCHLORIDE ANHYDROUS, GABAPENTIN, |
||||
| 341 | 25087289 |
US |
61 | 1 |
Myocardial infarction, Incorrect route of product administration, Accidental exposure to product, Incorrect dose administered by device, Rehabilitation therapy, Injection site bruising, |
||||
EVOLOCUMAB, EVOLOCUMAB, |
||||
| 342 | 25087576 |
US |
||
Accidental exposure to product, No adverse event, |
||||
IODIXANOL, |
||||
| 343 | 25087681 |
US |
61 | 2 |
Neoplasm malignant, Wrong technique in product usage process, Injury associated with device, Accidental exposure to product, Off label use, Incorrect route of product administration, Injection site haemorrhage, |
||||
ERENUMAB-AOOE, ERENUMAB-AOOE, |
||||
| 344 | 25087964 |
US |
2 | |
Accidental exposure to product, Hypoaesthesia, |
||||
HALOPERIDOL DECANOATE, |
||||
| 345 | 25088015 |
US |
77 | 2 |
Hypoacusis, Accidental exposure to product, Wrong technique in product usage process, Device difficult to use, Incorrect dose administered by device, |
||||
EVOLOCUMAB, |
||||
| 346 | 25089308 |
US |
33 | 2 |
Accidental exposure to product, Wrong technique in product usage process, Injection site discharge, |
||||
FREMANEZUMAB-VFRM, |
||||
| 347 | 25089367 |
US |
2 | |
Accidental exposure to product, Device malfunction, Product dose omission issue, |
||||
SECUKINUMAB, |
||||
| 348 | 25089391 |
US |
66 | 2 |
Accidental exposure to product, Injection site haemorrhage, Drug dose omission by device, Wrong technique in product usage process, |
||||
EVOLOCUMAB, |
||||
| 349 | 25089424 |
US |
1 | |
Incorrect dose administered by device, Accidental exposure to product, |
||||
SECUKINUMAB, |
||||
| 350 | 25090151 |
US |
39 | 1 |
Device deployment issue, Accidental exposure to product, Product dose omission issue, |
||||
GOLIMUMAB, |
||||
| 351 | 25090436 |
US |
37 | 1 |
Device deployment issue, Accidental exposure to product, Injection site bruising, Product dose omission issue, |
||||
GUSELKUMAB, |
||||
| 352 | 25090574 |
US |
57 | 2 |
Product dose omission issue, Needle issue, Accidental exposure to product, |
||||
GUSELKUMAB, |
||||
| 353 | 25091079 |
US |
2 | |
Eye pruritus, Lacrimation increased, Accidental exposure to product, |
||||
FLUOROURACIL, |
||||
| 354 | 25091364 |
US |
8 | 1 |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 355 | 25091394 |
US |
2 | |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 356 | 25091423 |
US |
2 | |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 357 | 25091433 |
US |
24 | 1 |
Dermatitis atopic, Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 358 | 25091502 |
US |
62 | 1 |
Injection site pain, Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 359 | 25091519 |
US |
||
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 360 | 25091539 |
US |
65 | |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 361 | 25091596 |
US |
2 | |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 362 | 25091661 |
US |
65 | 1 |
Accidental exposure to product, Exposure via skin contact, |
||||
INSULIN GLARGINE, |
||||
| 363 | 25091663 |
US |
48 | 2 |
Accidental exposure to product, Exposure via skin contact, |
||||
INSULIN GLARGINE, |
||||
| 364 | 25091706 |
US |
6 | 2 |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 365 | 25091734 |
US |
44 | 2 |
Accidental exposure to product, Exposure via skin contact, |
||||
INSULIN GLARGINE, |
||||
| 366 | 25091757 |
US |
48 | 2 |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 367 | 25091802 |
US |
56 | 2 |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 368 | 25091841 |
CA |
2 | |
Accidental exposure to product, Device occlusion, |
||||
GOLIMUMAB, |
||||
| 369 | 25091943 |
US |
1 | |
Product dose omission issue, Device defective, Needle issue, Accidental exposure to product, |
||||
GUSELKUMAB, |
||||
| 370 | 25081786 |
US |
13 | 1 |
Injection site pain, Exposure via skin contact, Wrong technique in device usage process, Accidental exposure to product, |
||||
BELIMUMAB, LISINOPRIL, HYDROXYCHLOROQUINE, |
||||
| 371 | 25081862 |
US |
62 | 2 |
Device issue, Incorrect dose administered, Physical product label issue, Accidental exposure to product, |
||||
USTEKINUMAB, USTEKINUMAB, |
||||
| 372 | 25081896 |
US |
2 | |
Accidental exposure to product, Exposure via skin contact, Product use in unapproved indication, |
||||
DUPILUMAB, |
||||
| 373 | 25082258 |
US |
9 | 2 |
Injection site haemorrhage, Exposure via skin contact, Accidental exposure to product, |
||||
DUPILUMAB, |
||||
| 374 | 25082301 |
US |
59 | 2 |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 375 | 25082312 |
US |
74 | 2 |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 376 | 25082928 |
US |
2 | |
Accidental exposure to product, Injection site urticaria, Injection site erythema, Device leakage, Device deployment issue, Exposure via skin contact, Device delivery system issue, |
||||
ADALIMUMAB, |
||||
| 377 | 25082947 |
US |
13 | 1 |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 378 | 25083265 |
US |
34 | 2 |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, PROMETHAZINE HYDROCHLORIDE, RIZATRIPTAN BENZOATE, |
||||
| 379 | 25083433 |
US |
41 | 2 |
Exposure via skin contact, Accidental exposure to product, Wrong technique in product usage process, |
||||
ALBUTEROL SULFATE, |
||||
| 380 | 25083765 |
CL |
54 | 2 |
Meningitis aseptic, Headache, Neck pain, Leukocytosis, Neutrophilia, Meningism, Altered state of consciousness, Pyrexia, Vomiting, Accidental exposure to product, |
||||
IBUPROFEN, IBUPROFEN CAPSULES 200 MG, IBUPROFEN TABLETS USP, 200MG, IBUPROFEN ORAL, IBUPROFEN 200MG, IBUPFROFEN, IBUPROFEN TABLET, FILM-COATED, IBUPROFEN 200 MG, IBUPROFEN CAPSULE, |
||||
| 381 | 25083786 |
US |
65 | 1 |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 382 | 25083965 |
US |
||
Accidental exposure to product, Vasoconstriction, |
||||
OXYMETAZOLINE HYDROCHLORIDE, |
||||
| 383 | 25084016 |
US |
2 | |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 384 | 25084168 |
US |
1 | |
Accidental exposure to product, Product dose omission issue, Syringe issue, |
||||
GUSELKUMAB, GUSELKUMAB, |
||||
| 385 | 25084971 |
US |
2 | |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 386 | 25085051 |
US |
1 | |
Accidental exposure to product, Nausea, |
||||
| 387 | 25085554 |
US |
1 | |
Accidental exposure to product, Exposure via skin contact, Incorrect dose administered by device, Device leakage, |
||||
SOMATROPIN, SOMATROPIN, |
||||
| 388 | 25085572 |
US |
60 | 2 |
Thinking abnormal, Migraine, Accidental exposure to product, Drug dose omission by device, Wrong technique in product usage process, Injury associated with device, Therapy partial responder, Constipation, |
||||
ERENUMAB-AOOE, ERENUMAB-AOOE, UBROGEPANT, |
||||
| 389 | 25085985 |
US |
1 | |
Exposure via skin contact, Accidental exposure to product, Circumstance or information capable of leading to medication error, Device malfunction, Device delivery system issue, |
||||
ADALIMUMAB, ADALIMUMAB-FKJP, ADALIMUMAB-AATY, ADALIMUMAB-ADAZ, |
||||
| 390 | 25086016 |
US |
73 | 2 |
Accidental exposure to product, Device difficult to use, Drug dose omission by device, Injection site pain, |
||||
EVOLOCUMAB, |
||||
| 391 | 25086182 |
US |
7 | 2 |
Anuria, Acute kidney injury, Toxicity to various agents, Hypotension, Electrocardiogram QT prolonged, Accidental exposure to product, Product use in unapproved indication, |
||||
SOTALOL HYDROCHLORIDE, SOTALOL HYDROCHLORIDE TABLES AF, SOTALOL HYDROCHLORIDE TABLETS AF, SOTALOL HYDROCHLORIDE, SOTALOL HYDROCHLORIDE TABLES AF, SOTALOL HYDROCHLORIDE TABLETS AF, WARFARIN, WARFARIN, |
||||
| 392 | 25086491 |
US |
45 | 1 |
Injection site pain, Accidental exposure to product, Device leakage, |
||||
FREMANEZUMAB-VFRM, |
||||
| 393 | 25086523 |
US |
63 | 2 |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, LEVOTHYROXINE, |
||||
| 394 | 25086666 |
US |
39 | 2 |
Device defective, Accidental exposure to product, Product dose omission issue, |
||||
USTEKINUMAB, USTEKINUMAB, |
||||
| 395 | 25086668 |
US |
68 | 2 |
Injury associated with device, Accidental exposure to product, |
||||
EVOLOCUMAB, |
||||
| 396 | 25081237 |
US |
68 | 2 |
Injection site pain, Eczema, Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 397 | 25081254 |
US |
34 | 2 |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 398 | 25081281 |
US |
74 | 1 |
Accidental exposure to product, Exposure via skin contact, Incorrect dose administered, |
||||
INSULIN GLARGINE, |
||||
| 399 | 25081285 |
US |
2 | |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 400 | 25081300 |
US |
8 | 2 |
Product storage error, Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
disclaimer
Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. We may limit or otherwise restrict your access to the API in line with our Terms of Service.
terms
license
last_updated
2025-04-28